A newspaper report has revealed that British drug maker GlaxoSmithKline (GSK) is to make thousands of chemical compounds that have the potential to cure malaria available for research.
Andrew Witty, GSK chief executive, told the Guardian on Wednesday that multinational drug companies must balance social responsibility with their need to make profits to please shareholders.
The company will publish details of 13,500 chemical compounds from its library that have the potential to act against the parasite that causes deadly malaria in sub-Saharan Africa, the Guardian said.
In a major speech in New York, Witty will also announce an eight-million-dollar (4.9-million-pound, 5.6-million-euro) fund to pay for scientists to investigate the chemicals, according to the paper.
About Mosquito Diseases
Mosquito-borne diseases, like malaria, filaria, dengue, etc are common in places conducive of mosquito breeding. Swamps, ponds and stagnated drainage provide optimal breeding ground for mosquitoes.
Mosquito-borne diseases, like malaria, filaria, dengue, etc are common in places conducive of mosquito breeding. Swamps, ponds and stagnated drainage provide optimal breeding ground for mosquitoes.
"It is trying to create a permissiveness around scientific research in an area where we know the marketplace isn't going to stimulate massive research," he added.
Advertisement
Health Effects of Global Warming
Greenhouse effect causes excessive heat to build up in the earth’s atmosphere causing global warming and affects the environment and health.
Greenhouse effect causes excessive heat to build up in the earth’s atmosphere causing global warming and affects the environment and health.
It is a development on a speech almost a year ago by Witty, when he vowed to put all drugs for neglected diseases in a so-called "patent pool", waiving intellectual property rights so any researcher could examine them, the Guardian reported.
Advertisement
Source-AFP
RAS
